Compare CVS Health Corp (CVS) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Texas Instruments Incorporated — how do they compare? CVS Health Corp trades at $103.33 (market cap $135.48B), while Texas Instruments Incorporated trades at $309.8 (market cap $278.08B). The key difference: Texas Instruments Incorporated is far larger — about 2.1× CVS Health Corp's market cap, and CVS Health Corp pays the higher dividend (2.51%). Which is the better fit depends on your goals.
| CVS | TXN | |
|---|---|---|
Market Cap | $135.48B | $278.08B |
Sector | Health | Technology |
52-Week High | $106.18 | $332.35 |
52-Week Low | $58.75 | $153.33 |
Enterprise Value | $202.02B | $287.03B |
Dividend Yield | 2.51% | 1.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
Texas Instruments (TXN) trades at $305.55, down 1.91% with a bearish technical signal. The company shows improving fundamentals with Q1 2026 earnings beat ($1.68 vs $1.36 expected) and revenue growth to $17.68B in 2025. Recent CFO transition to Julie Knecht and strong AI-related demand from data centers provide positive catalysts. Valuation remains elevated with P/E of 51.04 and P/S of 14.78, while maintaining strong profitability with 29.11% net margin and 32.18% ROE.
TXN presents a mixed outlook with solid fundamentals offset by premium valuation. The stock offers exposure to growing AI infrastructure demand and operational improvements, but faces risks from competitive pressures and debt levels. Analyst consensus leans bullish with $317.20 price target, though technical indicators suggest near-term caution. The current price near pivot point resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
